Tower Research Capital LLC (TRC) - ASCENDIS PHARMA A/S ownership

ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 1 filers reported holding ASCENDIS PHARMA A/S in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.3%.

Quarter-by-quarter ownership
Tower Research Capital LLC (TRC) ownership history of ASCENDIS PHARMA A/S
ValueSharesWeighting
Q3 2023$30,713
-87.6%
328
-88.2%
0.00%
-87.5%
Q2 2023$247,847
+134599.5%
2,777
+61.5%
0.01%
+33.3%
Q1 2023$184
-24.9%
1,719
-14.3%
0.01%
-40.0%
Q4 2022$245
-99.8%
2,005
+96.0%
0.01%
+400.0%
Q3 2022$106,000
-72.2%
1,023
-75.0%
0.00%
-77.8%
Q2 2022$381,000
+27.4%
4,094
+60.9%
0.01%
+200.0%
Q1 2022$299,000
-33.3%
2,545
-23.5%
0.00%
-62.5%
Q4 2021$448,000
+293.0%
3,325
+364.4%
0.01%
+166.7%
Q3 2021$114,000
-69.1%
716
-74.5%
0.00%
-70.0%
Q2 2021$369,000
+1319.2%
2,805
+1316.7%
0.01%
Q1 2021$26,000
-68.7%
198
-60.2%
0.00%
-100.0%
Q4 2020$83,000
+130.6%
498
+114.7%
0.00%
Q3 2020$36,000
-93.7%
232
-94.0%
0.00%
-100.0%
Q2 2020$567,000
+990.4%
3,838
+736.2%
0.02%
+666.7%
Q1 2020$52,000
-50.9%
459
-49.9%
0.00%
-57.1%
Q2 2019$106,000
-38.7%
916
-37.9%
0.01%
-30.0%
Q1 2019$173,000
+2062.5%
1,476
+1183.5%
0.01%
Q2 2018$8,000
+700.0%
115
+784.6%
0.00%
Q1 2018$1,000
-50.0%
13
-77.2%
0.00%
Q3 2017$2,000570.00%
Q2 2017$0
-100.0%
0
-100.0%
0.00%
-100.0%
Q1 2017$32,000
+166.7%
1,133
+86.0%
0.00%
+200.0%
Q4 2016$12,000
-29.4%
609
-27.4%
0.00%
-50.0%
Q3 2016$17,000
-19.0%
839
-47.5%
0.00%0.0%
Q2 2016$21,000
+600.0%
1,599
+813.7%
0.00%
Q3 2015$3,000175
+1066.7%
0.00%
Q2 2015$0
-100.0%
15
-98.9%
0.00%
-100.0%
Q1 2015$23,0001,3230.00%
Other shareholders
ASCENDIS PHARMA A/S shareholders Q4 2023
NameSharesValueWeighting ↓
RA Capital Management 7,387,900$1,177,557,00016.32%
Q Global Advisors, LLC 66,714$10,634,0008.85%
Ghost Tree Capital, LLC 120,000$19,127,0005.59%
Vivo Capital, LLC 760,606$121,233,0005.44%
Spyglass Capital Management LLC 1,378,887$219,781,0005.04%
Avoro Capital Advisors LLC 1,980,000$315,592,0004.96%
Eversept Partners, LP 445,203$70,960,9064.93%
Sofinnova Investments, Inc. 499,824$79,667,0004.72%
Eventide Asset Management 1,748,648$278,717,0003.68%
Baker Brothers Advisors 4,541,604$723,886,0003.18%
View complete list of ASCENDIS PHARMA A/S shareholders